- Home
- XERS vs PGEN Comparison
XERS vs PGEN Comparison
Compare XERS & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XERS
- PGEN
- Stock Information
- Founded
- XERS 2005
- PGEN 1998
- Country
- XERS United States
- PGEN United States
- Employees
- XERS N/A
- PGEN N/A
- Industry
- XERS Biotechnology: Pharmaceutical Preparations
- PGEN Biotechnology: Pharmaceutical Preparations
- Sector
- XERS Health Care
- PGEN Health Care
- Exchange
- XERS Nasdaq
- PGEN Nasdaq
- Market Cap
- XERS 628.7M
- PGEN 454.6M
- IPO Year
- XERS 2018
- PGEN N/A
- Fundamental
- Price
- XERS $5.16
- PGEN $1.35
- Analyst Decision
- XERS Strong Buy
- PGEN Strong Buy
- Analyst Count
- XERS 5
- PGEN 4
- Target Price
- XERS $6.10
- PGEN $7.33
- AVG Volume (30 Days)
- XERS 2.3M
- PGEN 1.2M
- Earning Date
- XERS 05-08-2025
- PGEN 05-13-2025
- Dividend Yield
- XERS N/A
- PGEN N/A
- EPS Growth
- XERS N/A
- PGEN N/A
- EPS
- XERS N/A
- PGEN N/A
- Revenue
- XERS $222,551,000.00
- PGEN $3,925,000.00
- Revenue This Year
- XERS $31.75
- PGEN $189.12
- Revenue Next Year
- XERS $21.09
- PGEN $1,093.07
- P/E Ratio
- XERS N/A
- PGEN N/A
- Revenue Growth
- XERS 29.88
- PGEN N/A
- 52 Week Low
- XERS $1.72
- PGEN $0.65
- 52 Week High
- XERS $6.07
- PGEN $2.17
- Technical
- Relative Strength Index (RSI)
- XERS 63.30
- PGEN 40.83
- Support Level
- XERS $4.26
- PGEN $1.48
- Resistance Level
- XERS $4.77
- PGEN $1.66
- Average True Range (ATR)
- XERS 0.28
- PGEN 0.11
- MACD
- XERS 0.08
- PGEN -0.01
- Stochastic Oscillator
- XERS 91.32
- PGEN 28.74
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.